184 related articles for article (PubMed ID: 19739126)
21. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Senthilkumar K; Arunkumar R; Elumalai P; Sharmila G; Gunadharini DN; Banudevi S; Krishnamoorthy G; Benson CS; Arunakaran J
Cell Biochem Funct; 2011 Mar; 29(2):87-95. PubMed ID: 21308698
[TBL] [Abstract][Full Text] [Related]
22. RNA interference-directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo.
Pulukuri SM; Gondi CS; Lakka SS; Jutla A; Estes N; Gujrati M; Rao JS
J Biol Chem; 2005 Oct; 280(43):36529-40. PubMed ID: 16127174
[TBL] [Abstract][Full Text] [Related]
23. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
24. S179D prolactin primarily uses the extrinsic pathway and mitogen-activated protein kinase signaling to induce apoptosis in human endothelial cells.
Ueda EK; Lo HL; Bartolini P; Walker AM
Endocrinology; 2006 Oct; 147(10):4627-37. PubMed ID: 16840547
[TBL] [Abstract][Full Text] [Related]
25. A molecular mimic of phosphorylated prolactin (S179D PRL) secreted by eukaryotic cells has a conformation with an increased positive surface charge compared to that of unmodified prolactin.
Ueda EK; Soares CR; Bartolini P; DeGuzman A; Lorenson MY; Walker AM
Biochemistry; 2009 Jul; 48(29):6887-97. PubMed ID: 19555049
[TBL] [Abstract][Full Text] [Related]
26. Calcitonin receptor-stimulated migration of prostate cancer cells is mediated by urokinase receptor-integrin signaling.
Thomas S; Chiriva-Internati M; Shah GV
Clin Exp Metastasis; 2007; 24(5):363-77. PubMed ID: 17487556
[TBL] [Abstract][Full Text] [Related]
27. DU145 human prostate carcinoma invasiveness is modulated by urokinase receptor (uPAR) downstream of epidermal growth factor receptor (EGFR) signaling.
Mamoune A; Kassis J; Kharait S; Kloeker S; Manos E; Jones DA; Wells A
Exp Cell Res; 2004 Sep; 299(1):91-100. PubMed ID: 15302576
[TBL] [Abstract][Full Text] [Related]
28. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
[TBL] [Abstract][Full Text] [Related]
29. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
[TBL] [Abstract][Full Text] [Related]
30. S179D-human PRL, a pseudophosphorylated human PRL analog, is an agonist and not an antagonist.
Bernichtein S; Kinet S; Jeay S; Llovera M; Madern D; Martial JA; Kelly PA; Goffin V
Endocrinology; 2001 Sep; 142(9):3950-63. PubMed ID: 11517174
[TBL] [Abstract][Full Text] [Related]
31. Pseudophosphorylated prolactin (S179D PRL) inhibits growth and promotes beta-casein gene expression in the rat mammary gland.
Kuo CB; Wu W; Xu X; Yang L; Chen C; Coss D; Birdsall B; Nasseri D; Walker AM
Cell Tissue Res; 2002 Sep; 309(3):429-37. PubMed ID: 12195299
[TBL] [Abstract][Full Text] [Related]
32. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer.
Kim J; Luo W; Chen DT; Earley K; Tunstead J; Yu-Lee LY; Lin SH
Cancer Res; 2003 Jan; 63(2):386-93. PubMed ID: 12543792
[TBL] [Abstract][Full Text] [Related]
33. Sprouty-4 inhibits transformed cell growth, migration and invasion, and epithelial-mesenchymal transition, and is regulated by Wnt7A through PPARgamma in non-small cell lung cancer.
Tennis MA; Van Scoyk MM; Freeman SV; Vandervest KM; Nemenoff RA; Winn RA
Mol Cancer Res; 2010 Jun; 8(6):833-43. PubMed ID: 20501643
[TBL] [Abstract][Full Text] [Related]
34. Intracerebroventricular administration of the prolactin (PRL) receptor antagonist, S179D PRL, disrupts parturition in rats.
Nephew BC; Amico J; Cai HM; Walker AM; Bridges RS
Reproduction; 2007 Jul; 134(1):155-60. PubMed ID: 17641097
[TBL] [Abstract][Full Text] [Related]
35. Metformin inhibits the proliferation of human prostate cancer PC-3 cells via the downregulation of insulin-like growth factor 1 receptor.
Kato H; Sekine Y; Furuya Y; Miyazawa Y; Koike H; Suzuki K
Biochem Biophys Res Commun; 2015 May; 461(1):115-21. PubMed ID: 25862373
[TBL] [Abstract][Full Text] [Related]
36. Phosphatase of regenerating liver 3 (PRL-3) is overexpressed in human prostate cancer tissue and promotes growth and migration.
Vandsemb EN; Bertilsson H; Abdollahi P; Størkersen Ø; Våtsveen TK; Rye MB; Rø TB; Børset M; Slørdahl TS
J Transl Med; 2016 Mar; 14():71. PubMed ID: 26975394
[TBL] [Abstract][Full Text] [Related]
37. Different forms of prolactin have opposing effects on the expression of cell cycle regulatory proteins in differentiated mammary epithelial cells.
Wu W; Chen YH; Ueda E; Tan D; Bartolini P; Walker AM
Oncol Res; 2006; 16(2):75-84. PubMed ID: 16898268
[TBL] [Abstract][Full Text] [Related]
38. Expression of prolactin receptor and response to prolactin stimulation of human NK cell lines.
Sun R; Li AL; Wei HM; Tian ZG
Cell Res; 2004 Feb; 14(1):67-73. PubMed ID: 15040892
[TBL] [Abstract][Full Text] [Related]
39. Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting.
Thomas LN; Merrimen J; Bell DG; Rendon R; Goffin V; Too CK
Prostate; 2014 May; 74(7):732-42. PubMed ID: 24615730
[TBL] [Abstract][Full Text] [Related]
40. Central infusions of the recombinant human prolactin receptor antagonist, S179D-PRL, delay the onset of maternal behavior in steroid-primed, nulliparous female rats.
Bridges R; Rigero B; Byrnes E; Yang L; Walker A
Endocrinology; 2001 Feb; 142(2):730-9. PubMed ID: 11159845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
